Self-injections Market by Type, Usage, Distribution Channel, Therapeutic Areas Application

List of Tables

[195 Pages Report] The Self-injections Market size was estimated at USD 54.00 billion in 2023 and expected to reach USD 60.64 billion in 2024, at a CAGR 12.72% to reach USD 124.87 billion by 2030.

Self-injections refer to the products used to administer medication to themselves intramuscularly, subcutaneously, or intravenously without the immediate assistance of healthcare professionals. Self-injections are used for treatments that require regular and long-term care, such as insulin for diabetes, hormones for hormone replacement therapy and fertility treatments, and biologics for chronic conditions. Self-injection devices are widely used to increase autonomy and can improve treatment adherence by eliminating the need for healthcare provider administration. An elevating prevalence of chronic diseases, the need for home-based healthcare, advancements in drug delivery technology, and a growing patient preference for self-administration have improved the usage of self-injections in recent years. However, the requirement for significant investment in research and development, patient safety and comfort concerns, and the need for cold chain storage and logistics for biologics limit the product penetration of self-injections. Recognition of digitization and patient-centricity leads to opportunities for integrating smart technology into self-injection devices. Innovations focusing on connectivity can provide data collection, patient monitoring, and adherence tracking, guiding personalized treatment modalities for self-injections. Moreover, the supportive government approvals for self-injections are further expanding the scope of the market.

KEY MARKET STATISTICS
Base Year [2023]	USD 54.00 billion
Estimated Year [2024]	USD 60.64 billion
Forecast Year [2030]	USD 124.87 billion
CAGR (%)	12.72%

Type: Rising preference for pen injectors to manage chronic diseases

Auto-injectors are designed for convenient use and can administer a precise dose of medication with minimal training. Auto-injectors are used for the delivery of life-saving drugs in emergencies. The need-based preference for auto-injectors is high among patients who require immediate and reliable administration of drugs, often without the assistance of healthcare professionals. Needle-free injectors offer an alternative to traditional syringe injections, removing the need for needles. Needle-free injectors use a high-pressure, narrow jet of the injection liquid to penetrate the skin to deliver the medication. Individuals with needle phobia mainly prefer needle-free injectors or those who require frequent injections, such as diabetic patients who may otherwise experience needle fatigue. Pen injectors are widely used to manage chronic diseases, allowing insulin or growth hormone self-administration. Pen injectors are portable, discreet, and relatively easy to use, appealing to patients who need to administer medication regularly while maintaining an active lifestyle. Wearable injectors, also known as patch pumps, are devices that adhere to the patient's body and provide continuous or controlled delivery of drugs over an extended period. Wearable injectors are primarily used by patients who require long-term therapies. Auto-injectors and pen injectors are generally favored for their ease of use and reliability. In contrast, needle-free and wearable injectors cater to patients seeking a less invasive or more flexible approach to medication delivery.

Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination

Disposable self-injection devices are single-use injectors preferred for their convenience, safety, and the reduced risk of cross-contamination. Disposable self-injection devices are often chosen by patients requiring short-term medication regimens or those prioritizing the ease of not having to manage the maintenance of the device. Disposable injectors are preferred for diseases with a high risk of infection transmission. Reusable self-injection devices are multi-use systems that offer cost benefits over time and are favored by patients with chronic conditions requiring long-term medication delivery. Reusable self-injection devices are cost-effective, necessitate regular maintenance and are designed for durable use. Reusable injectors are preferred for long-term medication regimens. Disposable injectors offer convenience and safety, especially for patients not requiring long-term medication.

Distribution Channel: Emerging penetration of self-injections on online platforms

Hospital pharmacies primarily serve inpatients and outpatients directly connected to medical facilities. Patients who have been prescribed self-injection therapies during a hospital stay often receive their initial supply of self-injection equipment directly from the hospital pharmacy. Patients requiring specialized instruction on the use of self-injection devices or seeking high-touch support and guidance prefer hospital pharmacies. The rise of eCommerce has extended to the pharmaceutical field, with online pharmacies offering convenience, discretion, and lower prices. Online pharmacies are particularly well-suited for those who are already familiar with their self-injection regimen and prefer home delivery. Patients who prioritize convenience, have mobility and transportation challenges or have a stable self-injection regime choose online pharmacies highly. Private clinics offer personalized care and cater to patients looking for a certain continuity of care with a healthcare provider they trust. Private clinics can be beneficial for receiving self-injection therapies that require consistent monitoring and follow-up with the healthcare practitioner. Hospital pharmacies are preferred for their immediate accessibility and patient education resources, online pharmacies for convenience and potential cost savings, and private clinics for personalized, ongoing care.

Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues

Self-injection therapies are pivotal for the treatment of autoimmune diseases, including rheumatoid arthritis and lupus. Biological agents, including adalimumab and etanercept, are administered via self-injection to manage inflammation and modify disease progression. In the management of AIDS, self-injectable formulations of antiretroviral drugs may enhance adherence by providing less frequent dosing options. Self-injectable epinephrine auto-injectors are life-saving devices for individuals with severe allergies. Self-injections allow for immediate treatment in the case of an allergic reaction, preventing potentially fatal anaphylaxis. For oncology patients, self-injectables such as granulocyte colony-stimulating factors (G-CSF) help manage chemotherapy-induced neutropenia. Self-administration can mitigate the need for frequent healthcare visits and support the continuity of cancer treatment. Self-injectable therapies in the treatment of irritable bowel disorders, including Crohn's disease, involve anti-inflammatory and immunosuppressive drugs, which are vital in controlling symptoms and inducing long-term remission. Self-administered injectable medications, including beta-interferon, are a mainstay in the treatment regimen for multiple sclerosis patients to assist in managing symptoms and slow the progression of the disorder.

In psoriasis, self-injectable biologics target specific pathways within the immune system to reduce the overactive inflammatory response. Self-injectable emergency drugs, designed for rapid administration in crises, include treatments for acute allergic reactions, severe hypoglycemia, and narcotic overdoses, exemplified by epinephrine, glucagon, and naloxone auto-injectors, respectively. Epinephrine auto-injectors are the first line of defense during anaphylactic shocks, a severe, potentially life-threatening allergic reaction. Self-injectable treatments for migraines offer rapid relief of migraine symptoms. Self-injections can abort migraine attacks more quickly than oral medications, which is beneficial for patients with severe symptoms or those experiencing nausea and vomiting. Self-injectables used in hormone replacement therapies provide a consistent delivery method for hormones, including testosterone, estrogen, or progesterone, benefiting patients with hormonal deficiencies or in transgender care. Beta-interferon self-injections are used primarily to treat multiple sclerosis, reduce inflammation, and decrease the frequency of relapse episodes. Erythropoietin (EPO) self-injectables are essential for patients with chronic kidney disease to combat anemia. Erythropoietin (EPO) self-injectables stimulate red blood cell production and help to reduce the need for blood transfusions. Self-injectable follicle-stimulating hormone (FSH) plays a crucial role in fertility treatments. It stimulates ovary follicle growth in women and spermatogenesis in men. Low molecular weight heparin self-injections are commonly used for anticoagulation in patients at risk for thrombosis to provide an easy-to-use option for long-term outpatient anticoagulation therapy. Self-injected insulin is a cornerstone treatment for diabetes management that allows individuals to dose insulin according to their blood glucose levels and dietary intake, providing flexibility and better glycemic control. For osteoporosis patients, self-injected parathyroid hormone can help improve bone density by stimulating new bone growth, an essential aspect of managing severe osteoporosis. Parkinson's disease patients may benefit from self-injectable medications that can provide symptomatic relief or slow disease progression.

Regional Insights

The self-injections market in the Americas is driven by a strong emphasis on patient-centric care, advanced healthcare infrastructure, and an increase in biologic drug approvals that require patient-friendly administration. Consumers are becoming increasingly aware of self-care options, including self-injection devices, which align with convenience. Government initiatives to reduce hospital stays and promote self-administration of medication also contribute to the penetration of self-injections in the Americas. In the European Union, market growth for self-injection devices is supported by an aging population, the prevalence of chronic diseases, and a strong inclination toward self-management of these conditions. The EU's rigorous regulatory framework ensures high safety standards for self-injection devices. Furthermore, several EU countries have been active in running patient education programs to encourage the adoption of self-injection practices. In the Middle East and Africa, substantial investments in healthcare infrastructure and an increasing incidence of lifestyle-related diseases show promising growth for the self-injections market. In the Asia-Pacific region, rapid economic growth and increased healthcare expenditure are major drivers for the self-injections market. The government's emphasis on pharmaceutical innovation and the surging prevalence of chronic diseases are boosting demand. Furthermore, a technologically advanced healthcare system and an aging population enable the market for self-injection devices in the Asia Pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Self-injections Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Self-injections Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Self-injections Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Antares Pharma, Inc. by Halozyme, Inc., AstraZeneca plc, Baxter International, Inc., Becton, Dickinson and Company, Credence MedSystems, Inc., DALI Medical Devices Ltd., Eli Lilly and Company, Enable Injections, Inc., Gerresheimer AG, GlaxoSmithKline plc, Insulet Corporation, Johnson & Johnson Services, Inc., Medmix AG by Sulzer Ltd., Merck KGaA, Molex LLC by Koch Industries, Inc., Mylan N.V. by Viatris Inc., Novo Nordisk A/S, Owen Mumford Limited, PenJet Corporation, Pfizer Inc., PharmaJet, Inc., Recipharm AB, Sanofi S.A., SCHOTT AG, SHL Medical AG, Terumo Corporation, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services, Inc., and Ypsomed Group.

Market Segmentation & Coverage

This research report categorizes the Self-injections Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Auto-Injectors
- Needle-free Injectors
- Pen Injectors
- Wearable Injectors

Usage
- Disposable
- Reusable

Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Private Clinics

Therapeutic Areas Application
- Autoimmune Diseases
  - AIDS
  - Allergies
  - Cancer
  - Irritable Bowel Disorders
  - Multiple Sclerosis
  - Psoriasis

Emergency Drugs
- Anaphylactic Socks
- Migraine

Hormone Replacement Therapies
- Beta-Interferon
- Erythropoietin
- Follicle Stimulating Hormone
- Heparin
- Insulin
- Parathyroid Hormone
- Parkinson's

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Self-injections Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Self-injections Market?

3. What are the technology trends and regulatory frameworks in the Self-injections Market?

4. What is the market share of the leading vendors in the Self-injections Market?

5. Which modes and strategic moves are suitable for entering the Self-injections Market?

Product Code: MRR-03050D1B2DB4

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rapid prevalence of chronic diseases and rheumatoid arthritis
  - 5.1.1.2. Wide availability of self-injections for fertility treatments
- 5.1.2. Restraints
  - 5.1.2.1. Potential risk of product recall
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing government approvals for self-injections worldwide
  - 5.1.3.2. Technological advancements in self-injection devices
- 5.1.4. Challenges
  - 5.1.4.1. Limited awareness and administration challenges associated with self-injections
5.2. Market Segmentation Analysis
- 5.2.1. Type: Rising preference for pen injectors to manage chronic diseases
- 5.2.2. Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination
- 5.2.3. Distribution Channel: Emerging penetration of self-injections on online platforms
- 5.2.4. Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues
5.3. Market Trend Analysis
- 5.3.1. Rising incidents of diabetes and chronic diseases creating need for self-injections in the Americas
- 5.3.2. Growing investment in healthcare infrastructure and innovation in self-injections devices in APAC region
- 5.3.3. Supportive government approvals for self-injections in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Self-injections Market, by Type

6.1. Introduction
6.2. Auto-Injectors
6.3. Needle-free Injectors
6.4. Pen Injectors
6.5. Wearable Injectors

7. Self-injections Market, by Usage

7.1. Introduction
7.2. Disposable
7.3. Reusable

8. Self-injections Market, by Distribution Channel

8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Private Clinics

9. Self-injections Market, by Therapeutic Areas Application

9.1. Introduction
9.2. Autoimmune Diseases
9.3. Emergency Drugs
9.4. Hormone Replacement Therapies

10. Americas Self-injections Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Self-injections Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Self-injections Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Micron Biomedical Receives Funds To Produce Needle-Free Vaccines
- 13.3.2. Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval
- 13.3.3. Altaviz introduces New Auto-Injector Platform For Drug Delivery
- 13.3.4. FDA Approves On-Body Injector for Self Administration of Pegcetacoplan for PNH
- 13.3.5. Civica Partners With Ypsomed For Insulin Injection Pen
- 13.3.6. Eitan Medical Completes Transition of Wearable Injectors Business
- 13.3.7. Coherus Announces U.S. Launch of UDENYCA Autoinjector
- 13.3.8. Ypsomed Enhances Self-Injection Device Platforms With Integrated Human Factors Services
- 13.3.9. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
- 13.3.10. US FDA Approves Tezspire For Self-Administration Using Pre-Filled Pen
- 13.3.11. Phillips-Medisize Expands Product Portfolio with Launch of a Pen Injector Platform Designed to Lower Pharma Costs, Risks and Market Barriers

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio